Key result
Understanding the contractile apparatus and detecting sarcomeric-protein gene mutations in hypertrophic cardiomyopathy can aid in prognosis, family screening, and future drug design.
Understanding the molecular basis of the cardiac contractile apparatus and sarcomeric mutations is important for prognostic screening in HCM and future drug design.
Answers are grounded in this paper and cite their sources.
May aid HCM prognosis and family screening; leaves open mutation-specific therapies for validation.
The contractile apparatus of muscle is a highly efficient and adaptable mechanism for producing movement and is exploited throughout the animal kingdom. Molecular biology is yielding important insights into the intricate functioning of muscular contraction, especially in the heart, and in explaining the genesis of inherited myopathies. Mutational analyses of the sarcomeric-protein genes in conjunction with clinical assessment have shown that certain mutations indicate a more serious prognosis in HCM. Detecting these mutations in individuals is important for screening other family members for the disease. Understanding the contractile apparatus at the molecular level could contribute to the design of more effective drugs for treatment of cardiac diseases.
No takes yet. Share an insight, caveat, or question.
Davison et al. (2000) conducted a review in Hypertrophic cardiomyopathy (HCM) and inherited myopathies. Understanding the contractile apparatus and detecting sarcomeric-protein gene mutations in hypertrophic cardiomyopathy can aid in prognosis, family screening, and future drug design.
Synapse has enriched 10 related papers. Consider them for comparative context: